JP2012513390A5 - - Google Patents

Download PDF

Info

Publication number
JP2012513390A5
JP2012513390A5 JP2011542127A JP2011542127A JP2012513390A5 JP 2012513390 A5 JP2012513390 A5 JP 2012513390A5 JP 2011542127 A JP2011542127 A JP 2011542127A JP 2011542127 A JP2011542127 A JP 2011542127A JP 2012513390 A5 JP2012513390 A5 JP 2012513390A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
ring
heteroaryl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011542127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513390A (ja
JP5738196B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/006560 external-priority patent/WO2010074724A1/en
Publication of JP2012513390A publication Critical patent/JP2012513390A/ja
Publication of JP2012513390A5 publication Critical patent/JP2012513390A5/ja
Application granted granted Critical
Publication of JP5738196B2 publication Critical patent/JP5738196B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011542127A 2008-12-22 2009-12-15 オーロラキナーゼ阻害剤および抗cd20抗体の併用 Active JP5738196B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20350908P 2008-12-22 2008-12-22
US61/203,509 2008-12-22
PCT/US2009/006560 WO2010074724A1 (en) 2008-12-22 2009-12-15 Combination of aurora kinase inhibitors and anti-cd20 antibodies

Publications (3)

Publication Number Publication Date
JP2012513390A JP2012513390A (ja) 2012-06-14
JP2012513390A5 true JP2012513390A5 (US07794700-20100914-C00152.png) 2013-02-07
JP5738196B2 JP5738196B2 (ja) 2015-06-17

Family

ID=41664630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542127A Active JP5738196B2 (ja) 2008-12-22 2009-12-15 オーロラキナーゼ阻害剤および抗cd20抗体の併用

Country Status (13)

Country Link
US (3) US20100183601A1 (US07794700-20100914-C00152.png)
EP (1) EP2376082B1 (US07794700-20100914-C00152.png)
JP (1) JP5738196B2 (US07794700-20100914-C00152.png)
KR (1) KR101741168B1 (US07794700-20100914-C00152.png)
CN (1) CN102264368B (US07794700-20100914-C00152.png)
AU (1) AU2009330727B2 (US07794700-20100914-C00152.png)
BR (1) BRPI0923579A2 (US07794700-20100914-C00152.png)
CA (1) CA2747326C (US07794700-20100914-C00152.png)
ES (1) ES2468391T3 (US07794700-20100914-C00152.png)
HK (1) HK1160766A1 (US07794700-20100914-C00152.png)
MX (1) MX2011006725A (US07794700-20100914-C00152.png)
RU (1) RU2535032C2 (US07794700-20100914-C00152.png)
WO (1) WO2010074724A1 (US07794700-20100914-C00152.png)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009330727B2 (en) 2008-12-22 2016-07-28 Millennium Pharmaceuticals, Inc. Combination of Aurora kinase inhibitors and anti-CD20 antibodies
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
WO2014153509A1 (en) * 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
IL59316A (en) 1979-02-07 1983-07-31 Sparamedica Ag Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
KR19990087585A (ko) 1996-03-08 1999-12-27 돈 리사 로얄 신경학적 활성제로서의 아졸로벤즈아제핀 유도체
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
EP1026167B1 (en) 1997-09-29 2003-03-05 Meiji Seika Kaisha Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CN101259270A (zh) * 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
WO2001034194A1 (en) * 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
WO2001052353A2 (en) * 2000-01-12 2001-07-19 Emag Technologies L.L.C. Low cost compact omni-directional printed antenna
KR20030016250A (ko) * 2000-04-25 2003-02-26 아이덱 파마슈티칼즈 코포레이션 중추신경계 림프종 치료용 리툭시맵의 초내 투여
ES2265452T3 (es) 2000-12-21 2007-02-16 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
ES2290529T3 (es) 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
JP2006517949A (ja) 2003-02-17 2006-08-03 ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ キナーゼ阻害剤としての四環系ピラゾール誘導体、前記誘導体の製造方法、および前記誘導体を含む医薬組成物
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315657D0 (en) 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20050025605A1 (en) * 2003-07-30 2005-02-03 Vrana John J. Locator stud and method of assembly
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
RS50568B8 (sr) 2004-05-14 2019-08-30 Millennium Pharm Inc Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1781653A1 (en) 2004-07-05 2007-05-09 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
JP2008506714A (ja) 2004-07-16 2008-03-06 サネシス ファーマシューティカルズ, インコーポレイテッド オーロラキナーゼインヒビターとして有用なチエノピリミジン
CA2580151C (en) 2004-11-15 2014-02-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched .beta.-lactams using candida antarctica
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
MX2007008008A (es) 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EP1836199A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
US7485661B2 (en) 2005-01-18 2009-02-03 Pfizer Italia S.R.L. Heterobicyclic pyrazole derivatives as kinase inhibitors
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
KR101487027B1 (ko) 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
AR056763A1 (es) 2005-11-03 2007-10-24 Vertex Pharma Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen.
MX2008008320A (es) * 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
CN100346830C (zh) * 2005-12-28 2007-11-07 上海交通大学医学院附属瑞金医院 一种治疗b细胞淋巴瘤的药物组合物
CN102633783A (zh) * 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
TW200808311A (en) 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2007132221A1 (en) 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
GB0609530D0 (en) 2006-05-12 2006-06-21 Cyclacel Ltd Combination
WO2007132220A1 (en) 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
EP2037919A2 (en) * 2006-06-30 2009-03-25 Schering Corporation Method of using substituted piperidines that increase p53 activity
JP2010500352A (ja) 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090023743A1 (en) * 2007-05-09 2009-01-22 Abbott Laboratories Inhibitors of protein kinases
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
AU2009330727B2 (en) 2008-12-22 2016-07-28 Millennium Pharmaceuticals, Inc. Combination of Aurora kinase inhibitors and anti-CD20 antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
EP2496604B1 (en) * 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
US8653064B2 (en) * 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate

Similar Documents

Publication Publication Date Title
JP2012513390A5 (US07794700-20100914-C00152.png)
LUC00155I2 (US07794700-20100914-C00152.png)
JP2008535902A5 (US07794700-20100914-C00152.png)
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
JP2006182786A5 (US07794700-20100914-C00152.png)
JP2006507265A5 (US07794700-20100914-C00152.png)
RU2011130566A (ru) Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JP2005511698A5 (US07794700-20100914-C00152.png)
JP2013507415A5 (US07794700-20100914-C00152.png)
JP2009536620A5 (US07794700-20100914-C00152.png)
JP2010510215A5 (US07794700-20100914-C00152.png)
JP2007538092A5 (US07794700-20100914-C00152.png)
CY1113209T1 (el) Νεα παραγωγα πυρρολο [3,2-d] πυριμιδιν-4-ονης και η χρηση τους στη θεραπεια
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
JP2005511532A5 (US07794700-20100914-C00152.png)
JP2007517807A5 (US07794700-20100914-C00152.png)
JP2011505356A5 (US07794700-20100914-C00152.png)
JP2004505047A5 (US07794700-20100914-C00152.png)
RU2007124492A (ru) Комбинации, включающие эпотилоны и ингибиторы протеинтирозинкиназы, и их фармацевтическое применение
NO20041631L (no) Piperazinderivater med CCR1 reseptor antagonist
JP2017502092A5 (US07794700-20100914-C00152.png)
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
JP2011509302A5 (US07794700-20100914-C00152.png)
CY1108061T1 (el) Παραγωγα κιναζολινης ως src αναστολεις κινασης τυροσινης
JP2018502141A5 (US07794700-20100914-C00152.png)